

Market Data

Nutriband Inc. Nasdaq: NTRB

Industry	Pharma
Fiscal Year	Jan. 31
Price ¹	\$3.65
52 Week Range ¹	\$1.53-\$5.92
Market Cap ¹	\$40.0M
Shares Out.	11.0M
Float	3.7M
Avg. Vol (90-day)	34,607
Cash (mrq) ²	\$0.5M
LT Debt (mrq)	\$0.0M
Revenue (ttm)	\$2.1M

¹ As of May 2, 2024 ² does not include proceeds from \$8.4M private placement in April 2024

Auditor:

Sadler, Gibb & Associates, LLC

Legal Counsel: Michael Paige Law PLLC

Transfer Agent: Equiniti Trust Company

nutriband.com

Company Overview

Nutriband is a pioneering US-based pharmaceutical company focused on the development and commercialization of transdermal technologies that improve the safety, comfort, and efficacy of FDA-approved drugs, benefitting patients, physicians, and payers. Nutriband's lead product technology, AVERSA[™], is an abuse deterrent transdermal technology that incorporates aversive agents to prevent the abuse, diversion, misuse and accidental exposure of drugs with abuse potential, such as opioids, a \$22.8 billion global market.

The Company's first application for AVERSA[™] is an abuse-deterrent fentanyl transdermal patch which it is being developed to provide clinicians and patients a safe extended-release patch for chronic pain. The goal is to make opioid-based pain treatments safe for all who need them. AVERSA[™] technology has received patent protection in the US, EU, Australia, Japan, Mexico, and Russia, with patent protection pending in Canada. With anticipated peak annual sales of up to \$200 million upon FDA approval, and a strategic partnership with Kindeva for commercial development, Nutriband stands poised for significant growth. Nutriband's diversified structure, including revenue-generating subsidiaries and in-house manufacturing capabilities, solidifies its position as a unique player in the biopharma sector, promising investors a blend of innovation, sustainability, and market potential.



Investment Highlights

- Revolutionary AVERSA[™] abuse-deterrent transdermal technology mitigates the risk of drug abuse, diversion, and accidental exposure
- Targeting opioid crisis with AVERSA[™] Fentanyl addressing a global market valued at \$22.8 billion
- AVERSA[™] Fentanyl anticipated to reach peak annual sales of \$80 million to \$200 million upon FDA approval
- Streamlined 505(b)(2) NDA regulatory pathway requires only a single Phase 1 trial, significantly reducing the time and cost of development
- AVERSA[™] Fentanyl is eligible for an expedited six-month FDA review
- Strong IP with patent protection in major markets including the US, EU, Australia, Japan, Mexico, and Russia, with pending patents in Canada
- Diversified business model includes revenue-generating subsidiaries that support the company's financial sustainability and reduce its reliance on external funding for research and development activities

RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time. The information contained herein is not a representation or warranty and is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc., our specialists, advisors, and partners will not be liable to any person or entity (fincluding but not limited to lost profils, isos of opportunities, trading losses and damages that may arise out of the use of information provided to any person or entity (including but not limited to lost profils, isos of opportunities, trading losses and damages that may rese out of the use of information provided to any person or entity (including but not limited to lost profils, isos of opportunities, trading losses and damages that may rese ut of the user information provided to any person or entity (including but not limited to lost profils), the secarch reports, company profiles or in other investor relations materials or presentations. Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print. We strongly encourage all investors to conduct their own research before making any investo

Nasdaq: NTRB





Value Proposition

Nutriband presents a compelling opportunity, standing at the forefront of addressing the global opioid crisis with its revolutionary AVERSA[™] abuse-deterrent transdermal technology. Nutriband's lead product, AVERSA[™] Fentanyl, is targeting peak annual sales of \$80 million to \$200 million upon FDA approval. Nutriband is pursuing a streamlined 505(b)(2) NDA regulatory pathway for AVERSA[™] Fentanyl, requiring only a single Phase 1 trial with the potential for an expedited six-month FDA review further accelerates the path to market.

Nutriband's robust IP portfolio, with patents secured in major markets worldwide and additional patents pending, safeguards its innovations, ensuring long-term competitiveness and market exclusivity. The company's diversified business model, bolstered by revenue-generating subsidiaries, provides a strong foundation and minimizes reliance on external funding for R&D.

Nutriband embodies a unique convergence of innovation, significant societal value, and strong growth prospects. With a streamlined path to market, clear vision, established strategic partnerships, and commitment to addressing one of healthcare's most pressing challenges, Nutriband is well-positioned for success.

	(19) World Intellectual Property Organization International Bureau (43) International Publication Date 30 July 2015 (30.07.2015) WIPO PC	(10) International Publication Number WO 2015/112563 A2
	International Patent Classification: AddX 9/70 (2005.01) International Application Number:	Creek, GA 30022 (US). SMITH, Alan; 736 Greenvic Avenue, Ne, Atlanta, GA 30305 (US). GAULDING, Ja frey, C., 5258 Fox Hill Court, Peachnee Corners, G
	PCT/US2015/012196	30092 (US). (J) Agents: FOX, Jennifer, L. et al.; Brinks Giben & Lice P.O. Box 110285, Research Triangle Park, NC 2779 (US).
(26) (30)	Filing Langenger English (pr. 2016) English Pridicition Langenger English Pridicition Langenger US Pridicition Langenger US 619900 Jones 22 January 2014 (22:01, 2014) US 619900 Jones 2014 (22:01, 2014) US 62014 (72) 20 Jance 2014 (2006, 2014) US 62014 (72) 10 Jance 2014 (2006, 2014) US 62014	1) Designated States (solvers) enformatic indiminus), for ex- food of entormal provention multiplicity, FAI, Ko, K, AJ, AO, AT, AU, AZ, BA, BB, DG, BB, BG, BB, BW, FB BC, CA, CH, CA, CN, CO, CR, CU, CZ, ZH, DF, KD, DD, DD, ZE, CF, FE, FG, JS, FF, GB, GD, GG, GH, GH, GF, HY, HB, HH, DD, LL, SH, BS, JS, PK, JS, KK, KN, KY, KY, KK, ZL, LC, LK, LK, LK, LU, LY, MA, MB, MS, MS, MS, MN, AMN, ANA, MY, ANA, ANA, RA, KN, NN, NY, ANA SH, SH, SH, SH, SH, SH, SH, SH, SH, SH,
(72)	Inventors: ENSCORE, David, James, 1028 Wetherby (B Way, Johns Creck, GA 30022 (US), TAGLIAFERRI, Frank; 128 Winnons Drive, Decatar, GA 30030 (US), DAMON, Sizven, Paul 3920 Merrivanther Woods, Johns	4) Designated States rankers otherwise indicated, for eve- kind of regional protection available): ARIPO (BW, G GM, KF, LR, LS, MW, MZ, NA, RW, SD, SL, ST, S TZ, UG, ZM, ZW), Eurnian (AM, AZ, BY, KG, KZ, R)
_		
	TINE ABUSE AND MISUSE DETERRENT TRANSDERMAL	[Continued on next page

Leadership Team



Gareth Sheridan Founder and CEO Nutriband



Serguei Melnik Founder and President Nutriband



Dr. Alan Smith President 4P Therapeutics FDA Expert Committee on Complex Generics



Dr. Jeff Patrick CSO Nutriband



Gerald Goodman CFO Nutriband



Paddy Ryan CTO Nutriband



President Pocono Pharmaceutical



Tyler Overk Head of Active Intelligence



Dianna Mather VP Finance

RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this webbale at any time. The information contained hed to be used as the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained hed Colip Companies, Inc. or for any offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc. or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information provided to any person or entity (including but not limited to bet) set of the subset. In its research treports, company profiles company profiles or in other investor relations materials and presentations. Stock market investing is inherently risky. RedChip Companies is not responsible for any gans or tosses that result from the opinions expressed on this website, in its research reports, company profiles and the Scaturacy or incompleteness, reliable, and the search reports, company profiles and investors to conduct their own research before making any investment decision. For more information on stock market investing visit the Securities and Berode and the search reports, and the search reports, and the search reports. Second and the search reports, and the search reports, and the second and there decision. For more information o